PDS Biotechnology Corp Payments for Restructuring
PDS Biotechnology Corp (PDSB) reported Payments for Restructuring of $498.19 thousand for the 9-month period ending 2020-09-30, per its 10-K filed 2021-03-18.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsForRestructuring · last filed 2021-03-18
- PDS Biotechnology Corp payments for restructuring for the quarter ending 2020-09-30 was $126.86K, a 70.19% decline year-over-year.
- PDS Biotechnology Corp payments for restructuring for the quarter ending 2020-06-30 was $143.03K.
- PDS Biotechnology Corp payments for restructuring for the quarter ending 2020-03-31 was $228.30K.
- PDS Biotechnology Corp payments for restructuring for the quarter ending 2019-12-31 was $360.15K.
- PDS Biotechnology Corp payments for restructuring for fiscal 2019 was $1.57M.
| Period end | Payments for Restructuring 3 month | Payments for Restructuring 6 month | Payments for Restructuring 9 month | Payments for Restructuring 12 month |
|---|---|---|---|---|
| 2020-09-30 | $126.86K derived: 10-K 9 month − 10-Q 6 month · filed 2021-03-18 | $269.89K derived: sum of 2 quarters · filed 2021-03-18 | $498.19K 10-K · filed 2021-03-18 | $858.33K derived: sum of 4 quarters · filed 2021-03-18 |
| 2020-06-30 | $143.03K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | $371.32K 10-Q · filed 2020-08-13 | $731.47K derived: sum of 3 quarters · filed 2020-08-13 | $1.16M derived: sum of 4 quarters · filed 2020-08-13 |
| 2020-03-31 | $228.30K 10-Q · filed 2020-05-13 | $588.45K derived: sum of 2 quarters · filed 2020-05-13 | $1.01M derived: sum of 3 quarters · filed 2020-05-13 | |
| 2019-12-31 | $360.15K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-27 | $785.69K derived: sum of 2 quarters · filed 2020-03-27 | $1.57M 10-K · filed 2020-03-27 | |
| 2019-09-30 | $425.54K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $1.21M 10-Q · filed 2019-11-07 | ||
| 2019-06-30 | $786.40K 10-Q · filed 2019-08-01 | |||
| 2018-06-30 | $524.46K 10-Q · filed 2018-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |